Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) Director Jason Rhodes sold 73,108 shares of the stock in a transaction on Thursday, April 23rd. The shares were sold at an average price of $19.19, for a total value of $1,402,942.52. Following the transaction, the director directly owned 11,286 shares of the company's stock, valued at approximately $216,578.34. The trade was a 86.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Dyne Therapeutics Stock Performance
Shares of NASDAQ DYN opened at $18.04 on Tuesday. The stock has a fifty day moving average price of $17.74 and a two-hundred day moving average price of $18.49. The company has a debt-to-equity ratio of 0.15, a quick ratio of 22.25 and a current ratio of 22.25. The firm has a market cap of $2.98 billion, a P/E ratio of -5.10 and a beta of 1.29. Dyne Therapeutics, Inc. has a 1 year low of $8.06 and a 1 year high of $25.00.
Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its quarterly earnings results on Monday, March 2nd. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.02). Research analysts forecast that Dyne Therapeutics, Inc. will post -2.94 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of brokerages have recently commented on DYN. HC Wainwright cut their price objective on Dyne Therapeutics from $60.00 to $50.00 and set a "buy" rating for the company in a research report on Tuesday, March 3rd. Morgan Stanley cut their price objective on Dyne Therapeutics from $50.00 to $47.00 and set an "overweight" rating for the company in a research report on Monday, March 2nd. Chardan Capital reiterated a "buy" rating and set a $38.00 price objective on shares of Dyne Therapeutics in a research report on Monday, March 9th. JPMorgan Chase & Co. cut their price objective on Dyne Therapeutics from $17.00 to $16.00 and set a "neutral" rating for the company in a research report on Tuesday, January 20th. Finally, Jefferies Financial Group reiterated a "buy" rating on shares of Dyne Therapeutics in a research report on Monday, March 9th. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $35.14.
View Our Latest Report on DYN
Institutional Trading of Dyne Therapeutics
A number of hedge funds have recently modified their holdings of DYN. Hilton Head Capital Partners LLC purchased a new stake in shares of Dyne Therapeutics in the first quarter valued at $26,000. Chung Wu Investment Group LLC purchased a new stake in shares of Dyne Therapeutics in the third quarter valued at $30,000. Strs Ohio purchased a new stake in shares of Dyne Therapeutics in the fourth quarter valued at $51,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Dyne Therapeutics by 25.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company's stock valued at $70,000 after purchasing an additional 1,109 shares in the last quarter. Finally, Aster Capital Management DIFC Ltd purchased a new stake in shares of Dyne Therapeutics in the fourth quarter valued at $84,000. Hedge funds and other institutional investors own 96.68% of the company's stock.
Dyne Therapeutics Company Profile
(
Get Free Report)
Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.
Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
